PharmaEssentia USA has secured FDA approval under BLA761166 for BESREMI (ropeginterferon alfa-2b) to treat adult polycythemia vera, marking a strategically important expansion into the myeloproliferative neoplasm market which is poised to drive significant commercial growth and strengthen the company’s oncology portfolio. This regulatory milestone provides PharmaEssentia with a distinct competitive advantage within the chronic blood disorder landscape, positioning the brand to capitalize on the unmet needs of a patient population requiring long-term management.